By Marianne Apostolides
Psilocybin, MDMA, and ketamine can lead to a new sense of self and a release from rigid rules for people with anorexia, bulimia, and binge-eating disorder.
Read on neo.life
CLEAR ALL
We’re seeing an explosion of medical research into psychedelics. Psilocybin, or shrooms, to treat major depressive disorder. Ayahuasca, a psychotropic plant medicine from the Amazon, and ibogaine, a potent hallucinogen from Africa, to treat addiction. LSD for anxiety.
Through this treatment plan, the patient was able to “reconceptualize her trauma” and “was able to move through difficult memories and emotions rather than letting them consume her,” explained U of O associate professor, Monnica Williams.
1
In the last two decades, researchers have started to reexamine psychedelics for their therapeutic potential. Though initial results seem promising, the research has a significant shortcoming: the lack of racial and ethnic diversity among research teams and study participants.
A new study finds widespread exclusion of minorities in psychedelic research.
A recent study found that even a single positive psychedelic experience may ease mental health symptoms associated with racial trauma experienced by Black, Indigenous, and people of color (BIPOC).
Demand from patients seeking help for their mental illnesses has led to underground use in a way that parallels black markets in the AIDS pandemic. This underground use has been most perilous for people of color, who face greater stigma and legal risks due to the War on Drugs.
A well-kept American secret is that the CIA-funded research that exploited incarcerated Black Americans along with other vulnerable groups in America’s hunt for a “mind-control” drug.
Eating disorders have historically been believed to primarily afflict heterosexual, affluent, cisgender, thin, white women.
The stereotypic image of those suffering from eating disorders is not as valid as once thought.
The entrepreneur and community leader on healing, boundaries, and tuning into yourself.